Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Adverse Effects Profile (Phase 2 Data) The Phase 2 NEJM 2023 trial reported the following adverse event profile
The primary mechanism of action involves: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels without causing hypoglycaemia when glucose levels are normal [3] [4] Suppressing glucagon release , thereby reducing glucose production by the liver Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake When administered as medication, GLP-1 receptor agonists mimic these natural effects but with enhanced duration and potency
However, more research is needed to support these claims
Brains were isolated and stained for human immunoglobulin G (hIgG) and c-Fos
doi:10.1074/jbc.M008212200
Also in the category: Dosie, Glone, DoseWise, and more The GLP-1 tracker category is moving fast, and several newer entrants Dosie, Glone, GLP-1 DoseWise, GLP Compass ship variations of dose logging and reminders
US$ 26.31
US$ 22.58
US$ 25.29
US$ 24.18
US$ 25.58
US$ 24.40
US$ 28.66
US$ 22.94
US$ 22.82
